Results 211 to 220 of about 1,824,368 (348)
Molecular Oncology, EarlyView.This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci +6 more
wiley +1 more source
The impact of genetic testing in retinitis pigmentosa on reproductive medicine. [PDF]
Indian J OphthalmolSorthiya B, Maitra P.
europepmc +1 more source
Landscape of BRAF transcript variants in human cancer
Molecular Oncology, EarlyView.We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda +5 more
wiley +1 more source
Egg donors' attitudes toward identifiability, offspring information, and genetic testing. [PDF]
Reprod Biol EndocrinolLassen E +3 more
europepmc +1 more source
Clinical rationale of genetic testing in dementia. [PDF]
, 1997 Giovanni B. Frisoni, Marco Trabucchi
openalex +1 more source
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren +16 more
wiley +1 more source
Unravelling the Global Tapestry of Genetic Ataxias: Epidemiology and Genetic Testing Approaches. [PDF]
Mov DisordRossi M +13 more
europepmc +1 more source